We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Intelligent Ultrasound Group Plc | MED | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 14.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 14.50 | 14.50 |
| Top Posts |
|---|
Posted at 16/11/2020 12:38 by 40 fathoms Timbo003, well spotted indeed. My own view is with respect to COVID and be it Caption or MED, AI powered lung ultrasound has missed the boat and is probably not going to become a major revenue source for either. |
Posted at 05/11/2020 07:17 by chillpill Barely anyone follows MED. Number of people watching their YouTube clips is very low. |
Posted at 04/11/2020 16:15 by babbler Lol iqai got FDA and triples. Med does nada. |
Posted at 30/10/2020 09:29 by w t tutte Never any drama with MED they just get on with it. Quality Company in just the right area and completely ignored by the market. This is a complete head scratcher to me. |
Posted at 02/10/2020 14:49 by w t tutte You could not want for a better partner and it is good to see that in the marketing of the new product the AI aspects are very prominent. I have been looking at MED for about a year now and so far I have to say I am impressed with how management have delivered on key milestones within their predicted time targets. |
Posted at 04/7/2019 09:24 by woolybadger62 Many stocks have gone low then re rated dramatically and now turn for MED with major commercial news |
Posted at 27/11/2018 16:58 by tullynessle Another Non-Regulatory RNS todayMedaphor Group PLC AI database exceeds 1 million images 27 November 2018 MedaPhor Group plc ("MedaPhor" or the "Company") MedaPhor's AI obstetric image database exceeds 1 million images MedaPhor, the intelligent ultrasound software and simulation company, is pleased to announce that its database used for training its artificial intelligence (AI) products now exceeds 1 million obstetric ultrasound images. Large image libraries are a prerequisite to creating AI solutions. These images have helped MedaPhor to develop its ScanNav(R) AI-based clinical software for ultrasound professionals. The one million mark is a significant milestone for the Company, as it will enable it to build on its ScanNav software for the global obstetric ultrasound market. MedaPhor's ScanNav intelligent ultrasound technology, which uses AI algorithms and deep learning techniques to automatically assess ultrasound images, is currently being piloted in UK hospitals to support sonographers carrying out the 20 week anatomy scan. ScanNav assists sonographers to ensure that the images they are taking conform to the UK Fetal Anomaly Screening Programme (FASP) protocol. In future, the software will also be capable of automatically recording required images during the ultrasound scan. Continued......... |
Posted at 23/11/2018 21:04 by tullynessle RNS Non-Regulatory today.Medaphor Group PLC MedaPhor commences clinical trial for AnatomyGuide 23/11/2018 3:56pm RNS Non-Regulatory MedaPhor commences clinical trial for AnatomyGuide MedaPhor (AIM:MED), the intelligent ultrasound software and simulation company, announces it is commencing a clinical trial within the Aneurin Bevan University Health Board to capture data for its AnatomyGuide artificial intelligence (AI) software for ultrasound-guided anaesthetic procedures such as peripheral nerve blocks. Increasingly, ultrasound-guided peripheral nerve blocks are being used as a safer and more cost-effective alternative to general anaesthesia but not all anaesthetists have the specialist knowledge of ultrasound anatomy to perform them. AnatomyGuide provides software support and guidance to aid less experienced clinicians during the procedure. Using deep-learning techniques on a data set of thousands of real-patient images, the technology is 'taught' to recognise key anatomical structures. Then, by highlighting these structures in real-time during an ultrasound-guided nerve block procedure, AnatomyGuide's AI makes it easier for clinicians to accurately target the nerve. The clinical data from the Aneurin Bevan clinical trial is expected to complete the required data set. Through the adoption of AnatomyGuide, it is hoped that hospitals will be able to increase the number of ultrasound-guided nerve blocks that they can perform. Principal Investigator and consultant anaesthetist, Dr David Burckett-St.Laurent, said: "AnatomyGuide will help tip the balance of safety and confidence in favour of performing regional anaesthesia. I feel privileged to work with a Welsh company that is leading the world in developing AI-based ultrasound software. Our aim is to make a real clinical difference to patients by increasing the availability of regional anaesthesia through cutting edge technology. It is very exciting." AnatomyGuide is being developed as part of an Innovate UK project funded within the government's AI and data grand challenge. Nicholas Sleep, CTO at MedaPhor, commented: "AnatomyGuide shows how strategic government investment can catalyse an innovative technology that we hope will make a real difference to NHS patient care. The team in Cardiff are excited to be working with Innovate UK in developing AI technology that has real-world applications and we look forward to completing the clinical trials with David and the Aneurin Bevan University Health Board." |
Posted at 17/11/2008 12:18 by findochty New applicationeyescreen® microdisplays deliver the big picture for Vuzix(TM) iWear® New video glasses use tiny P-OLED displays to match viewing experience of 44-inch screens Edinburgh, UK 14 November2008 - As one of the first commercially available ranges of video glasses, VuzixTM iWear® is using the eyescreen® full-colour organic microdisplay from MicroEmissive Displays to deliver large-screen viewing experiences to its new AV230XL device. The new video eyewear uses MED's microdisplays, which are similar in size to the human pupil, to equal the visual effect of a conventional 44-inch TV screen. The glasses can be connected to almost any video device such as a personal video player, cellphone, PC, or game terminal, and will enrich the user experience on offer from innovations such as mobile TV, video telephony and virtual reality. The sub-$200 selling price will open up exciting video experiences to a broad consumer market. "eyescreen® has played a major role in enabling Vuzix to realise its vision and deliver this new addition to the iWear range successfully to the market," said Bill Miller, CEO of MED. "This will create powerful new ways for people to enjoy many types of media and virtual reality, and I am delighted that MED has provided important technology to make it happen." The new AV230XL will allow consumers to experience the full richness of games and media wherever and whenever they like. MED's advanced technology solutions and expertise with microdisplays has been critical to Vuzix achieving their product performance goals. MED's Polymer Organic LED (P-OLED) technology is crucial to achieving high visual performance with an ultra-small form factor and low power. With integrated driver ICs as well as a digital interface to the host system, the eyescreen® microdisplay also solves important integration challenges for product designers and accelerates time to market. ends |
Posted at 04/1/2007 20:16 by ariane OLED-Info Q&A with Ian Underwood, Strategic Marketing Officer, MEDSubmitted by oled on Thu, 23/11/2006 - 12:41. Ron Mertens from OLED-Info.com recently had the opportunity to interview Ian Underwood, Strategic Marketing Officer and Co-Founder of MicroEmissive Display (MED). Ian is also the co-inventor of its P-OLED microdisplay technology. Prior to 1999 he was at The University of Edinburgh where he carried out pioneering research and development in the field of liquid crystal microdisplays between 1983 and 1999. Ian has recently co-authored a book about microdisplays. MicroEmissive Displays (MED) was founded in 1999 with the aim of developing and commercialising a new microdisplay technology using P-OLED materials. MED is a public company listed on the Alternative Investment Market of the London Stock Exchange. In september 2006 MED has announced that it has raised over $9 million, and has revealed its plans for a volume manufacturing facility for its polymer light emitting diode (P-OLED) microdisplay products. Q: First of all, thank you for accepting to do this interview session with us... Let's begin. Can you give a short description of MED? What it is that you do? MED develops, manufactures ands sells microdisplays based upon the hybrid technology of P-OLED/CMOS (read as P-OLED over CMOS). A microdisplay is a very-small active-matrix electronic display that is capable of showing TV-quality pictures. Microdisplays are optically magnified in order to produce a viewable image. Microdisplay-based systems have the unique advantage of being able to produce a viewable image that is much larger than the physical size of the unit that produces the image. An additional advantage (particularly for portable and personal electronics) is that microdisplays tend to operate at lower power than the equivalent direct-view display thus prolonging battery life. P-OLED is the solution-processable polymer version of Organic LED. Microdisplays are used in two main classes of applications - Projection data projectors rear-projection television Near-To-Eye (NTE) Hand-held = electronic viewfinders digital cameras video cameras night scopes (See in the dark) medical instruments Hands-free = Wearable displays Head mounted displays Video glasses MED's products address both parts of the NTE market. Q: How do your products compete with other microdisplays on the market? The competition to P-OLED/CMOS is two-fold transmissive miniature TFT-LCD and reflective liquid crystal on silicon (LCOS). Transmissive TFT-LCD does not scale very well to small pixel sizes where overall optical efficiency is small; fill-factor (the proportion of the area of each pixel that lights up) becomes small thus making pixelation artifacts more visible. Only low levels of electronic integration are possible, so more support chips are required. Reflective LCOS, on the other hand, suffers from complicated optics and the system complications of field sequential colour. Q:What advantages do you get from the P-OLED display? MED's P-OLED/CMOS technology offers High level of electronic integration (effectively display system on chip) No driver chip required (assuming BT656 digital video input signal) No backlight required Simple emissive optics (no polarization required) Ultra-low power consumption Superior image quality (contrast, pixelation) Q: Can you comment about eMagin's OLED microdisplays? With an early stage technology like OLEDs, many customers find it reassuring when there is more than one company developing products. It boosts their confidence in the generic technology. Q: Currently your web site describes only one product: eyescreen ME3204, a colour QVGA (320x240 pixel) microdisplay. Do you have plans for higher resolution displays? MED has a product roadmap that will involve the development of widescreen (16:9) and higher resolution components in due course. Q: You have just announced that you raised $9M to build your manufacturing plant. Can you give more details? In October we successfully completed a placing of new ordinary shares to raise approximately £5 million of new funds. The proceeds from this placing will help secure the company's planned move to volume manufacturing in 2007 in Dresden, Germany. We believe that this will enable MED to take advantage of what we consider to be significant market opportunities for our innovative product, eyescreen. Both the Saxony State Ministry for Economic Affairs and Labour and the Inward Investment Council for East Germany have been very supportive of MED and our move and have provided us with a letter of intent setting out the availability of material grant funding for the company. Q: You say you have some customers that already signed letters of intent. Can you name some of these customers or their products? The first letter of intent was received in June 2006 for volume product to commence in 2007. Discussions with most customers are carried out under mutual non-disclosure agreements, so we can't disclose customer names. Q: You are a CDT licensee, and seem to have a special relationship with them. Can you give some more info about your cooperation? MED has a license from CDT to use CDT's IP in its products. I would describe the relationship between the companies as close, cooperative, mutually beneficial and very healthy. MED certainly benefits from its close collaboration with CDT. In particular, the material and device expertise resident at CDT has been of great assistance to MED in developing its own device structure and manufacturing process. Q: Do you have plans for non P-OLED products? Such as OLED displays? MED is focusing very much on its core technology, bringing the new product to market and mass manufacturing. Q: eMagin decided that in addition to selling displays to OEM, they want to sell complete systems (i.e. their 3D visor product). Do you have any plans like that? MED's core competences include P-OLED device technology and microdisplay technology. MED is focusing very much on its core technology, the new product and mass manufacturing. Our expertise in systems is being utilized to help our customers develop their systems so as to maximize the benefits of using MED's microdisplay components. Q: When do you think we'll be able to buy an OLED TV, or computer screen? Domestic TV and flat panel monitors for computers are amongst the most demanding of applications, so we will see OLEDs in a range of other applications first such as MP3 players, mobile phones and cameras. MED's P-OLED microdisplays will soon emerge in electronic viewfinders and video glasses. As for large OLED TVs, these have been seen at trade shows over the last few years but it will be some time before they are sold in the shops. Q: Where do you see OLEDs in 5 years? Display products based on OLED technology will continue to penetrate the mainstream within the next 5 years. There will be an evolution from smaller to include larger displays and for the emergence of a whole host of non-display applications including OLED backlights for LCDs, OLED panels for lighting, and revolutionary products like OLED sticking plasters for the treatment of skin cancers. Q: I'm sure there are MED shareholders reading this interview. What do you have to say to them? What does the future hold? MED has a very promising technology that, even in its current early stage of development, offers clear advantages over mature incumbent technologies. MED's technology is capable of scaling and improvement for many years into the future. The company's current task is to begin to manufacture its new product, the eyescreen ME3204, in volume, to generate a significant revenue stream and to establish itself as a volume supplier of microdisplays. Thereafter we will begin to broaden our product portfolio. Thank you again for your time, I wish both you and MED good luck! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
